GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanoviricides Inc (AMEX:NNVC) » Definitions » 10-Year RORE %

NNVC (Nanoviricides) 10-Year RORE % : -6.57% (As of Sep. 2024)


View and export this data going back to 2005. Start your Free Trial

What is Nanoviricides 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Nanoviricides's 10-Year RORE % for the quarter that ended in Sep. 2024 was -6.57%.

The industry rank for Nanoviricides's 10-Year RORE % or its related term are showing as below:

NNVC's 10-Year RORE % is ranked worse than
50.85% of 590 companies
in the Biotechnology industry
Industry Median: -6.205 vs NNVC: -6.57

Nanoviricides 10-Year RORE % Historical Data

The historical data trend for Nanoviricides's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanoviricides 10-Year RORE % Chart

Nanoviricides Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.41 -9.58 -11.36 -24.23 -2.74

Nanoviricides Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.18 -13.23 -13.33 -2.74 -6.57

Competitive Comparison of Nanoviricides's 10-Year RORE %

For the Biotechnology subindustry, Nanoviricides's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanoviricides's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanoviricides's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Nanoviricides's 10-Year RORE % falls into.



Nanoviricides 10-Year RORE % Calculation

Nanoviricides's 10-Year RORE % for the quarter that ended in Sep. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( -0.76--2 )/( -18.87-0 )
=1.24/-18.87
=-6.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2024 and 10-year before.


Nanoviricides  (AMEX:NNVC) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Nanoviricides 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Nanoviricides's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanoviricides Business Description

Traded in Other Exchanges
Address
1 Controls Drive, Shelton, CT, USA, 06484
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Executives
Makarand Jawadakar director C.O NANOVIRICIDES, INC, 1 CONTROLS DRIVE, SHELTON CT 06484
Mark D. Day director C/O NANOVIRICIDES, INC., 1 CONTROLS DRIVE, SHELTON CT 06484
Milton Boniuk director C/O NANOVIRICIDES, INC., 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Anil Diwan director, 10 percent owner, officer: President 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Mukund S Kulkarni director C/O NANOVIRICIDES, INC., 135 WOOD ST, SUITE 205, WEST HAVEN CT 06516
Meeta Vyas officer: Chief Financial Officer 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516
Eugene Seymour director, 10 percent owner 666 THIRD AVENUE, NEW YORK NY 10017
Theracour Pharma, Inc. 10 percent owner 135 WOOD STREET, SUITE 205, WEST HAVEN CT 06516

Nanoviricides Headlines

From GuruFocus